Daiichi Sankyo’s ADC cancer drug, Enhertu, generated $3.7 billion in sales and is meeting expectations. However, challenges lie ahead for Datroway and the lead program with Merck. Despite U.S. approval for Datroway, Daiichi Sankyo faces hurdles in lung cancer development due to mixed study results and a recent setback with Merck on another ADC application.
Read more from biopharmadive.com
